Insider · CIK 0001463151
James E. Levine
Files at KZIA (KAZIA THERAPEUTICS LTD), CRDF (Cardiff Oncology, Inc.). First filing Dec 18, 2024, latest Dec 18, 2024.
In brief
James E. Levine files SEC Form 4 as CFO at CRDF (Cardiff Oncology, Inc.), and also at KZIA (KAZIA THERAPEUTICS LTD). Since Dec 18, 2024, James E. Levine has reported 1 open-market buy worth $37k and 0 open-market sells worth $0, the latest filed on Dec 18, 2024.
A track record needs three past buys with six months of prices behind them; James E. Levine has 0, so none is measured yet.
The newest scored trade: bought $37k of CRDF on Dec 16, 2024, filed Dec 18, 2024, scored 46 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRDF: Cardiff Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Cardiff Oncology, Inc. | $37k 7,716 shares | +13% | - |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 19, 2026 | KZIA KAZIA THERAPEUTICS LTD | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jun 23, 2026 |
| Mar 11, 2025 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +332,621 | $0.00 | $0 | 1,295,117 | Mar 13, 2025 |
| Dec 16, 2024 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stockindirect: By Wife | +2,564 | $3.83 | $9,820 | 62,564 | Dec 18, 2024 |
| Dec 17, 2024 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stockindirect: By Wife | +2,752 | $5.42 | $15k | 65,316 | Dec 18, 2024 |
| Dec 18, 2024 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stockindirect: By Wife | +2,400 | $5.00 | $12k | 67,716 | Dec 18, 2024 |
| Mar 7, 2024 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +205,008 | $0.00 | $0 | 962,496 | Mar 7, 2024 |
Questions about James E. Levine
Answered from the filings on this page, as of the latest one.
Is James E. Levine buying or selling?
Not in the last 12 months. James E. Levine's latest open-market trade on SEC Form 4 was bought $37k of CRDF on Dec 16, 2024.
How did James E. Levine's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James E. Levine has 0.
Where does James E. Levine file Form 4?
James E. Levine has filed Form 4 at CRDF (Cardiff Oncology, Inc.) as Chief Financial Officer; KZIA (KAZIA THERAPEUTICS LTD) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.